ModernMedicine Resource Center More Topics

Targeted Therapy Resource Center

RCC: Multiple pathways provide therapeutic targetsRead highlights from a presentation by Toni K. Choueiri, MD, at the Society of Urologic Oncology annual meeting.
Immunotherapies move toward FDA approval for urothelial CaTwo late-stage immunotherapy drugs for the treatment of urothelial carcinoma reach regulatory, research milestones.
Next-gen sequencing panel for renal Ca earns CLIA approvalThe genomic profiling tool distinguishes among the dominant three malignant and one benign renal cancer subtypes.
Oral agent improves survival in advanced RCC patientsOnce-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Bladder Cancer: Androgen receptor activation a potential therapeutic targetMultiple studies on exosomes, data from the IMvigor 210 trial of atezolizumab (TECENTRIQ), and research on prehabilitation for cystectomy were among the highlights in bladder cancer from the 2016 AUA annual meeting.
What anti-PD-L1 immunotherapy approval means for urologyUrologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
A new castration-resistant prostate cancer entity?Urology Times SUO internship program member Brandon Manley, MD, reports on an SUO presentation highlighting several interesting findings on advanced prostate cancer with variant histology.
  • 1
  • 2